Literature DB >> 29999126

[Sepsis hyperglycemia in the ICU: from the mechanism to the clinic].

Larissa Aleman1, Julia Guerrero1.   

Abstract

Stress hyperglycemia is frequently diagnosed in septic patients in critical care units (ICU) and it is associated with greater illness severity and higher morbimortality rates. In response to an acute injury, high levels of counterregulatory hormones such as glucocorticoids and catecholamines are released causing increased hepatic gluconeogenesis and insulin resistance. Furthermore, during sepsis, proinflammatory cytokines also participate in the pathogenesis of this phenomenon. Septic patients represent a subtype of the critical ill patients in the ICU: this metabolic disarrangement management strategies and insulin therapy recommendations had been inconsistent. In this article, we describe the pathophysiological mechanisms of stress hyperglycemia in critical patients including the action of hormones, inflammatory cytokines and tissue resistance to insulin. In addition, we analyzed the main published studies for the treatment of acute hyperglycemia in critical patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29999126     DOI: 10.4067/s0034-98872018000400502

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  3 in total

1.  Hyperglycemia minimally alters primary self-renewing human colonic epithelial cells while TNFα-promotes severe intestinal epithelial dysfunction.

Authors:  Johanna S Dutton; Samuel S Hinman; Raehyun Kim; Peter J Attayek; Mallory Maurer; Christopher S Sims; Nancy L Allbritton
Journal:  Integr Biol (Camb)       Date:  2021-06-15       Impact factor: 2.192

2.  Analysis of insulin resistance using the non-linear homeostatic model assessment index in overweight canines.

Authors:  Franco Gonzlez-Villar; Francisco Pérez-Bravo
Journal:  Vet World       Date:  2022-06-08

3.  Effect of glycemic gap upon mortality in critically ill patients with diabetes.

Authors:  Ran Lou; Li Jiang; Bo Zhu
Journal:  J Diabetes Investig       Date:  2021-08-03       Impact factor: 4.232

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.